AAA514 is listed as a product in 2 authorised or ongoing trials in the EU clinical trials register (CTIS). All registered phases are Phase 2. The sponsor with the most trials is Odense University Hospital. It does not appear under this name in the ClinicalTrials.gov records behind our other registers.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product named AAA514. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
[⁶⁸Ga]Ga-HKG301 PET/CT for staging and restaging patients with primary breast cancer: a phase II study (FAPILOUS)
2025-521324-29-00 · Neoplasms
|
Phase 2 | Authorised | Odense University Hospital | Denmark |
|
LuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu FAP 2286 in Participants with an Advanced Solid Tumor
2023-508995-12-01 · CTIS ↗ · Neoplasms
|
Phase 2 | Ongoing | Novartis Pharma AG | Italy, Spain, Belgium + 1 more |
| Lead sponsor | Trials |
|---|---|
| Odense University Hospital | 1 |
| Novartis Pharma AG | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| EU register (CTIS) | 2 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
2 authorised or ongoing trials in the EU clinical trials register (CTIS) list a product named AAA514, as of the registry sync on 1 October 2026. It is not named in the ClinicalTrials.gov records behind our Ireland, UK, USA, India and China registers.
Odense University Hospital (1) and Novartis Pharma AG (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public EU CTIS records by a daily sync. Nothing here describes how AAA514 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how AAA514 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists AAA514 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 1 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.